Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Miricorlilant · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Miricorlilant 600 mg | EXPERIMENTAL | Patients who meet the entry criteria will be randomized to receive 600 mg miricorilant for 26 weeks. |
| Miricorlilant 900 mg | EXPERIMENTAL | Patients who meet the entry criteria will be randomized to receive 900 mg miricorilant for 26 weeks. |
| Placebo | PLACEBO_COMPARATOR | Patients who meet the entry criteria will be randomized to receive placebo for 26 weeks. |
| Name | Type | Description |
|---|---|---|
| Miricorlilant | DRUG | Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing |
| Placebo | DRUG | Placebo for once-daily oral dosing |
Inclusion Criteria: * Have a diagnosis of schizophrenia * Are currently taking olanzapine, risperidone, paliperidone, or quetiapine and have gained weight from treatment while on these medications * Must be on a stable dose of medication for 1 month prior to Screening * Have a BMI ≥30 kg/m\^2. Exc...
Miricorilant is an investigational small molecule being developed for antipsychotic-induced weight gain (AIWG), a condition that can occur in patients taking antipsychotic medications. It is being studied in the psychiatry therapeutic area for this indication.
Miricorilant is being developed by Corcept Therapeutics Incorporated, a biopharmaceutical company traded on NASDAQ under the ticker CORT. The company is conducting clinical research to evaluate the drug's safety and efficacy for antipsychotic-induced weight gain.
Miricorilant is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied for its potential to address antipsychotic-induced weight gain in patients.
Miricorilant has been evaluated in a Phase 2 clinical trial with the identifier NCT04524403, known as the GRATITUDE II study. This randomized, double-blind, placebo-controlled trial enrolled 150 obese adult patients with schizophrenia who were taking antipsychotic medications. The study was conducted in the United States and has been completed.
No, Miricorilant is the drug being studied, while GRATITUDE II is the name of the clinical trial evaluating it. The trial, identified as NCT04524403, assessed the safety, efficacy, and pharmacokinetics of Miricorilant in patients with antipsychotic-induced weight gain.